Table 1.
Patients' characteristics at baseline
| Variable | N(%) |
|---|---|
| Age, years [mean (SD)] | 41.6 (11.9) |
| Males | 61 (81.3) |
| Risk factor IVDU | 6 (8) |
| BMI (< 25 Kg/m2) | 39 (52.7) |
| Viral load > 100.000 copies/mL | 26 (34.7) |
| CD4 T cell count < 200 cells/mm3 | 17 (22.7) |
| CD4/CD8 ratio < 0.4 | 42 (56) |
| Cigarette smokers | 35 (46.7) |
| HCV Ab positive | 11 (14.7) |
| CDC 93 clinical class A | 46 (65.7) |
| HAART: | |
| • TDF/FTC + EFV | 33 (44) |
| • TDF/FTC + ATV/r | 42 (56) |
| Phosphoraemia < 2.7 mg/dL | 19 (25.3) |
| 1,25 (OH)2 Vitamin D < 11 pg/mL | 19 (25.3) |
| Hyperparathyroidism (> 65 pg/mL) | 4 (5.3) |
| eGFR creatinine * < 90 mL/min | 26 (34.6) |
| eGFR cystatin C * < 90 mL/min | 15 (20.5) |
| OC, ng/mL [mean (SD)] | 19.86 (10) |
| CTx, ng/mL [mean (SD)] | 0.43 (0.26) |
| OPG, ng/mL [mean (SD)] | 0.83 (0.41) |
N number, SD standard deviation, IVDU intra-venous drug users, BMI body mass index, HAART highly active antiretroviral therapy, TDF tenofovir, FTC emtricitabine, EFV efavirenz, ATV/r atazanavir/ritonavir, eGFR estimated glomerular filtration rate, OC osteocalcin, CTx C-terminal cross-laps, OPG osteoprotegerin